BUPROPION AS A MODULATOR OF DRUG ACTIVITY
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
1 - 20 . (canceled)
21 . A method of treating agitation in Alzheimer's disease, comprising administering a dosage form by mouth once daily or twice daily to a human patient in need thereof, wherein the dosage form comprises about 105 mg of bupropion hydrochloride and about 45 mg of a dextromethorphan salt as the only therapeutically active compounds in the dosage form.
22 . The method of claim 21 , wherein the dosage form is a tablet.
23 . The method of claim 21 , wherein bupropion hydrochloride is in a sustained release formulation.
24 . The method of claim 23 , wherein the dextromethorphan salt is in an immediate release formulation.
25 . The method of claim 21 , wherein the dosage form is administered once daily by mouth for three days followed by twice daily by mouth thereafter for a total of at least 8 days, and wherein on the eighth day that the dosage form is administered, the C max of bupropion in the human patient is about 9×10 1 ng/mL.
26 . The method of claim 21 , wherein the dosage form is administered once daily by mouth for three days followed by twice daily by mouth thereafter for a total of at least 8 days, and wherein on the eighth day that the dosage form is administered, the AUC 0-12 of bupropion in the human patient is about 7×10 2 ng·hr/mL.
27 . The method of claim 21 , wherein the dextromethorphan salt is dextromethorphan hydrobromide.
28 . The method of claim 27 , wherein the dosage form is a tablet.
29 . The method of claim 27 , wherein bupropion hydrochloride is in a sustained release formulation.
30 . The method of claim 29 , wherein dextromethorphan hydrobromide is in an immediate release formulation.
31 . The method of claim 27 , wherein the dosage form is administered once daily by mouth for three days followed by twice daily by mouth thereafter for a total of at least 8 days, and wherein on the eighth day that the dosage form is administered, the C max of bupropion in the human patient is about 9×10 1 ng/mL.
32 . The method of claim 27 , wherein the dosage form is administered once daily by mouth for three days followed by twice daily by mouth thereafter for a total of at least 8 days, and wherein on the eighth day that the dosage form is administered, the AUC 0-12 of bupropion in the human patient is about 7×10 2 ng·hr/mL.
33 . The method of claim 27 , wherein the human patient is an extensive CYP2D6 metabolizer.
34 . The method of claim 33 , wherein the dosage form is administered once daily by mouth for three days followed by twice daily by mouth thereafter.
35 . The method of claim 21 , wherein the human patient is an extensive CYP2D6 metabolizer.
36 . The method of claim 35 , wherein the dosage form is a tablet.
37 . The method of claim 35 , wherein bupropion hydrochloride is in a sustained release formulation.
38 . The method of claim 37 , wherein the dextromethorphan salt is in an immediate release formulation.
39 . The method of claim 35 , wherein the dosage form administered once daily by mouth for three days followed by twice daily by mouth thereafter for a total of at least 8 days, and wherein on the eighth day that the dosage form is administered, the C max of bupropion in the human patient is about 9×10 1 ng/mL.
40 . The method of claim 35 , wherein the dosage form is administered once daily by mouth for three days followed by twice daily by mouth thereafter for a total of at least 8 days, and wherein on the eighth day that the dosage form is administered, the AUC 0-12 of bupropion in the human patient is about 7×10 2 ng·hr/mL.
41 . The method of claim 21 , wherein the dosage form is administered once daily by mouth for three days followed by twice daily by mouth thereafter.
42 . The method of claim 41 , wherein the human patient is an extensive CYP2D6 metabolizer.
43 . The method of claim 41 , wherein the dosage form is a tablet.
44 . The method of claim 41 , wherein bupropion hydrochloride is in a sustained release formulation.
45 . The method of claim 44 , wherein the dextromethorphan salt is in an immediate release formulation.